• Loading stock data…

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

Last Updated on November 22, 2022 by GlobeNewsWire

ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS(R)), announced today that management will participate in the following conferences in November and December 2022:

BTIG Ophthalmology DayFireside ChatTuesday, November 29, 2022 at 10:30 a.m. ET

Piper Sandler 34th Annual Healthcare ConferenceCorporate PresentationThursday, December 1, 2022 at 9:50 a.m. ET

Ophthalmology Innovation Summit (OIS) XIIPanel Discussion: Spotlight on Gene & Cell TherapyRetina Innovation Showcase: Corporate PresentationSaturday, December 3, 2022

Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech ConferenceOphthalmology Panel Discussion: Take A Look At What’s In Store For Wet AMD & Related Diabetic Eye DiseasesThursday, December 8, 2022 at 2:45 p.m. ET

A link to the live and archived webcasts may be accessed on the Clearside website under the Investors section: Events and Presentations.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS(R)). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector(R), enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE(R) (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin Remy Bernarda ir@clearsidebio.com(678) 430-8206

Source: Clearside Biomedical, Inc.




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: